About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 432 record(s)
Req # A-2022-000235
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-103634-644.Organization: Health Canada
August 2022
Req # A-2022-000236
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-100719-921.Organization: Health Canada
August 2022
Req # A-2022-000275
Adverse Drug Reaction (ADR). Report number: 000984504.Organization: Health Canada
August 2022
Req # A-2022-000276
Adverse Drug Reaction (ADR) for Dexilant. Report number: E2B_05168036. ADRs for Entyvio. Report numbers: E2B_05144393, E2B_05201553, E2B_05100649, E2B_05133754. ADRs for Vedolizumab. Report numbers: E2B_05140162, E2B_05186118, E2B_05110558,…Organization: Health Canada
August 2022
Req # A-2022-000280
Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_05100649, E2B_05185665, E2B_05096839. ADR for Mesalamine. Report number: E2B_05090601. ADR for C1 Esterase Inhibitor (Human). Report number: E2B_05098849. ADRs for Immunoglobulin (…Organization: Health Canada
August 2022
Req # A-2022-000282
Adverse Drug Reactions (ADRs). Report numbers: 000977325, E2B_04921399, 000978467, E2B_04875737, 000977213, E2B_04402148, E2B_04845335, 000978206, E2B_04920318, E2B_04580127.Organization: Health Canada
August 2022
Req # A-2022-000292
Adverse Drug Reactions (ADRs). Report numbers: E2B_03821961, E2B_04486099, E2B_04712176, E2B_04942699, E2B_04856187, E2B_04938771, E2B_04938745, E2B_04797467, E2B_04867666, 000975762.Organization: Health Canada
August 2022
Req # A-2022-000294
Adverse Drug Reactions (ADRs) for Intron A. Report numbers: E2B_03022099, E2B_03022079, E2B_03022075, E2B_02726169.Organization: Health Canada
August 2022
Req # A-2022-000295
Adverse Drug Reactions (ADRs) for Abilify. Report numbers: 000978703, 000980697, E2B_04984685, E2B_04986528, E2B_05006894, 000985149, 000985191. ADR for: Abilify maintena. Report numbers: E2B_05048808, E2B_05028169, 000982813.Organization: Health Canada
August 2022
Req # A-2022-000300
Adverse Drug Reactions (ADRs) for Celexa. Report numbers: 948953, E2B_03986567, E2B_03994182, E2B_01900496, E2B_04227929, E2B_03168677, 952226. ADRs for Trintellix. Report numbers: E2B_04003507, 950171, 949146.Organization: Health Canada
August 2022